The risk of seizures with primary brain tumors or brain metastases is about10–100%. Frequency of seizures depends upon tumor histology, location and their growth pattern. More common in low grade tumors, supratentorial and cortical based tumors.About 25% patients have seizures at initial presentation. There is no controversy regarding the use of antiepileptic drugs (AEDs) in patients with brain tumors who present with seizures but the prophylactic use of AEDs in brain tumor patients, who do not have seizures, continues to be debated. Most of trials used enzyme inducing AEDs for seizure prophylaxis and were having small sample size. These trials show no benefit of seizure prophylaxis. In this article we emphasize the need for a large multi–centric randomized controlled trial with sufficient statistical power and testing of newer antiepileptic drugs with better pharmaco–dynamic profile into the trials, to get the solid evidence by which we can formulate the individualized recommendation regarding seizure prophylaxiskeeping tumor characteristics, patient characteristics and newly available antiepileptic drugs (AEDs)  in our mind.